glioblastoma

[Laboratory Investigation] Brain tissues were clinically collected from 50 patients with glioblastoma and 35 patients with acute craniocerebral injury, followed by immunohistochemical detection of the expression patterns of Forkhead box M1, anterior gradient 2, and hypoxia-inducible factor-1α.

[Cancer Gene Therapy] Researchers found that TMEM158 expression in human glioma cells in the tumor core was significantly higher than that in noncancerous cells at the tumor edge using bioinformatics analysis.

[Communications Biology] Researchers demonstrated that SMAD specific E3 ubiquitin protein ligase 2 (SMURF2)Thr249 phosphorylation played an essential role in maintaining glioma stem cell (GSC) stemness and tumorigenicity. SMURF2 silencing augmented the self-renewal potential and tumorigenicity of patient-derived GSCs.

[Developmental Cell] F3-antibody-sorted glioblastoma cells exhibited stem cell gene expression, enhanced self-renewal in culture, drove tumor initiation and serial transplantation, and reconstituted tumor heterogeneity.

[NOXXON Pharma N.V.] NOXXON Pharma N.V. announced that the Data Safety Monitoring Board positively evaluated safety data from the initial four weeks of treatment of the first patient enrolled in the GLORIA clinical trial expansion arm.

[Bioengineered] Analysis of a dataset verified the prognostic value of PD-L1 and revealed an association between PD-L1 mRNA expression and the status of isocitrate dehydrogenase. Increased PD-L1 expression predicts unfavorable overall survival in glioblastoma.